NCT00209625CompletedPhase 1
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer：Hokkaido Gastrointestinal Cancer Study Group:HGCSG0001
Hokkaido Gastrointestinal Cancer Study Group2 sites in 1 country23 target enrollmentStarted: April 2000Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 23
- Locations
- 2
- Primary Endpoint
- objective tumor response
Study Overview
Brief Summary
We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen
Detailed Description
A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with histological stage IV colorectal cancer given irinotecan, leucovorin plus fluorouracil. The usefulness of this regimens as 1st line therapy for colorectal cancer was evaluated by the disease-free survival rate (DFR), median survival time (MST), incidence and severity of adverse event.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histological diagnosis of colorectral adenocarcinoma.
- •Measurable or assessable lesions.
- •Age: 18 ~ 75 years.
- •Performance Status (ECOG): 0 ~
- •No prior chemotherapy. Adjuvant chemotherapy is not defined as previous therapy.
- •No history of radiotherapy to the abdomen.
- •Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC 3,500/mm3 and 12,000/mm
- •Hb 10.0 g/dl. Platelet count 100,000/mm
- •GOT and GPT 2.5times the upper limit of normal (excluding liver metastasis). T-Bil 2.0mg/dl. Creatinine <1.5 mg/dl Normal ECG (not considering clinically unimportant arrhythmias and ischemic changes).
- •Predicted survival for >3 months.
- •Able to give written informed consent.
Exclusion Criteria
- •Severe pleural effusion or ascites.
- •Metastasis to the central nervous system (CNS).
- •Active gastrointestinal bleeding.
- •Active infection.
- •Diarrhea (watery stools).
- •Uncontrolled ischemic heart disease.
- •Serious complications (such as intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, or hepatic failure).
- •Active multiple cancer.
- •Severe mental disorder.
- •Pregnancy, possible pregnancy, or breast-feeding.
- •Flucytosine treatment
- •Gilbert's syndrome.
- •Judged to be ineligible for this protocol by the attending physician.
Outcomes
Primary Outcomes
objective tumor response
Secondary Outcomes
- Response duration, time to progression, median survival time, and safety
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 1
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal CancerColo-rectal CancerNCT03545711Chinese Academy of Medical Sciences42
Completed
Phase 1
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal CancersDuodenum CancerBile Duct CancerPancreatic CancerGastric CancerNCT00183846University of Southern California22
Unknown
Phase 1
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal CancerRectal CancerNCT01474187Fudan University60
Unknown
Phase 2
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer PatientsColoRectal CancerNCT03053167China Medical University, China100
Terminated
Phase 2
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and OligodendrogliomasOligodendrogliomaGliomaAstrocytomaNCT00360828H. Lee Moffitt Cancer Center and Research Institute10